Format

Send to

Choose Destination
Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Author information

1
Laboratory of Gynecologic Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium. an.coosemans@gmail.com.
2
Department of Gynecology and Obstetrics, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium. an.coosemans@gmail.com.
3
Laboratory of Gynecologic Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium.
4
Department of Human Genetics, KU Leuven, Leuven, Belgium.
5
Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, Brussels, Belgium.
6
Laboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
7
Department of Gynecology and Obstetrics, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.

Abstract

The immune system is a crucial player in the development of cancer. Once it is in imbalance and immunosuppressive mechanisms supporting tumor growth take over control, dendritic cell immunotherapy might offer a solution to restore the balance. There are several methods to manufacture dendritic cells but none of them has yet proven to be superior to others. In this chapter, we discuss the methodology using electroporation of mRNA encoding Wilms' tumor gene 1, survivin, and TriMix (mixture of caTLR4, CD40L, and CD70) to simultaneously load and mature dendritic cells.

KEYWORDS:

Dendritic cell; Electroporation; Survivin; TriMix; WT1; mRNA

PMID:
27236806
DOI:
10.1007/978-1-4939-3625-0_18
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center